Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81
Document › Details

Sage Group Inc., The. (9/28/14). "Press Release: The Sage Group Announces New Venture Capital Initiative – the $65M Joint Polish Investment Fund". Warsaw.

Region Region Poland
Organisations Organisation Sage Group Inc., The, Sage Europe
  Group Sage Group (Group)
  Organisation 2 JPIF I (Joint Polish Investment Fund I)
  Group Joint Polish Investment Fund (JPIF) (Group)
Products Product JPIF I (Joint Polish Investment Fund I)
  Product 2 consulting, business
Index terms Index term Joint Polish Investment Fund–Sage Group: consulting, 201409– supply service supporting concept + fundraising by Sage
  Index term 2 Joint Polish Investment Fund–SEVERAL: investment, 201503 first $42m closing of JPIF I supported by NCBR
Persons Person Orlowski, Marek (Joint Polish Investment Fund 201503 General Partner before Co-founder of Nepentes SA)
  Person 2 Nickelsen, Kreske (Joint Polish Investment Fund 201503 General Partner)

The Sage Group has announced that it is working with a team of investors and advisors to manage a new US$65 million healthcare and life science fund.

The Joint Polish Investment Fund (JPIF) is a closed Venture Capital Fund leveraged by additional €26m in the form of a subordinated loan (€21m) and a grant (€5m) from the Polish government. An additional €12M has also been committed by a strategic venture fund based in Warsaw, Adiuvo.

The fund will invest in early as well as mid stage Life Science companies in Central and Eastern Europe with an investment holding period of 3-5 years.

It will focus on areas with strong growth and high return potential like digital health, medical technology and nutraceuticals.

Poland is the rising star in Central Europe with a vibrant economy, high class scientific institutions, a healthy and liquid IPO environment for early stage companies, and a VC market which is just developing, thus offering attractive opportunities for first movers.

Due to the significant leverage by the Polish government the fund can buy equity positions which are 3-5 times higher than the committed fund capital, thus offering huge return opportunities.

The fund is domiciled in the Netherlands with an international team operating out of Warsaw. The Sage Group is supporting the fund in respect of corporate finance and opportunity assessment, and are based in Cambridge, UK, and Clinton, New Jersey, USA.

Marek Orlowski, General Partner and the head of the new JPIF fund, a Polish based venture-capital and advisory organization, said “I am very pleased by the fact that the Polish government agency (NCBR) responsible for managing this new venture capital program has made this major investment in the Life Sciences. We are also excited to be working with the Sage Group as advisors in raising the fund and strategic assessment of the numerous corporate opportunities we anticipate.” Dr. Orlowski said he has worked closely with the SAGE group for the last two years and is pleased that the group has achieved this milestone.

Dr. Orlowski was co-Founder of Nepentes SA, a manufacturer and supplier of pharmaceuticals. In 1997, Nepentes IPOed on the Warsaw Stock Exchange and in 2010, the business was sold to Sanofi-Aventis for about €106M, a strong return for investors. Since 2010, Dr. Orlowski has been a serial entrepreneur and business angel, investing in life-science companies in Poland and abroad.

The JPIF Fund will be managed by Dr. Orlowski and Kreske Nickelsen, an experienced venture fund manager with 16 years of experience in European Venture Capital including 3i and Aescap. She has managed funds, equity investments and partnering/business development projects in nearly all Western European countries. Kreske has broad experience from execution of over 60 transactions ranging from equity investments, licensing agreements, joint ventures to IPOs and trade sales.

Wayne Pambianchi of The Sage Group based in the USA said “We are very pleased to be working for this exciting program and we look forward to working with JPIF and other key parties on the implementation phase."

Dr. Bill Mason of The Sage Group based in Cambridge, UK, said “This is an exciting project for Sage which on the one hand will enable inward investment of resources including finance and assets into Poland and on the other hand will provide the resource to identify and nurture the outstanding life science technologies and companies incubating in the vibrant Polish nation."

The Sage Group ( is based in USA, Europe, Israel, Australia and Japan. Sage has specialized for nearly 20 years in strategic transactional consultancy for the pharma, biotech, medtech and diagnostics industries. Sage is focused on M&A and licensing transactions for its clients and the 9 Sage principals, based around the world, have completed more than 300 deals, with a total transaction volume in excess of US$5Bn.

About The Sage Group, Inc.

The Sage Group Inc. is a leader in the provision of strategic and transactional advice to health care companies in the pharmaceutical, diagnostics, medical device, biotechnology and life science fields. Sage currently maintains offices in USA, Europe, Israel, Australia and Japan. Since its founding in 1994, The Sage Group has served more than 200 clients in the US, Europe and Asia, and completed numerous transactions including divestitures, alliances, acquisitions and financings with values ranging from $5 million to $500 million.



Dr. Marek Orlowski

Kreske Nickelsen

Dr. Bill Mason
The Sage Group
44 7785 950134

Wayne Pambianchi
The Sage Group
1 908 2306170

Record changed: 2019-04-26


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Sage Group (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top